Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients
To investigate the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and to investigate any associations between this polymorphism and clinicopathological parameters and survival. Tumors and matched adjacent non-ca...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2013-07, Vol.19 (28), p.4568-4575 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4575 |
|---|---|
| container_issue | 28 |
| container_start_page | 4568 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 19 |
| creator | Shen, Yan-Ying Lu, Ya-Chao Shen, Dan-Ping Liu, Yuan-Jie Su, Xin-Ying Zhu, Guan-Shan Yin, Xiao-Lu Ni, Xing-Zhi |
| description | To investigate the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and to investigate any associations between this polymorphism and clinicopathological parameters and survival.
Tumors and matched adjacent non-cancer tissues were collected from 304 GC patients, and 5 mL of venous blood was collected from 62 GC patients and 392 age- and sex-matched healthy controls without cancer history from the same ethnic population. DNA was extracted, and direct sequencing analyses were performed to genotype the FGFR4 Gly388Arg polymorphism in all the samples. Differences in the genotype frequencies of the FGFR4 Gly388Arg polymorphism between GC patients and healthy controls were estimated using the χ(2) test. Binary logistic regression was used for all analysis variables to estimate risk as the ORs with 95%CIs. The relationships between the FGFR4 genotype and clinicopathological parameters were tested with the χ(2) test. The Kaplan-Meier product-limit method, the log-rank test, and the Cox regression model were applied to evaluate the effect of the FGFR4 genotype on the overall survival of patients with GC.
In the present GC cohort, 118 patients (38.8%) were homozygous for the Gly388 allele, 124 patients (40.8%) were heterozygous, and 62 patients (20.4%) were homozygous for the Arg388 allele. The frequencies of the Gly/Gly, Gly/Arg, and Arg/Arg genotypes in the healthy controls were 33.6%, 48.0%, and 18.4%, respectively. The distributions of genotypes (χ(2) = 3.589, P = 0.166) and alleles (χ(2) = 0.342, P = 0.559) of the FGFR4 Gly388Arg polymorphism were not different between the GC patients and the healthy controls. Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at |
| doi_str_mv | 10.3748/wjg.v19.i28.4568 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3725383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1416694431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-128ff3543d7ffee1fe651181bfdfdfbe57959dcd944b577141e6f7bd02e6aabf3</originalsourceid><addsrcrecordid>eNpVkc2L2zAQxUVp6Wa3vfdUdOzFWX3Zki-FELofENjL9liELI8cLbblSk6W_PdVSDZ0mcMMzLz3Bn4IfaNkyaVQt68v3XJP66VnainKSn1AC8ZoXTAlyEe0oITIouZMXqHrlF4IYZyX7DO6YrwmlHGxQH_ufBND05s04y6G13mLnbFziDiChek4CHzfH7hSq9jhKfSHIcRp69OA_YjXWz9CAtxlffQWWzNaiHgys4dxTl_QJ2f6BF_P_Qb9vvv1vH4oNk_3j-vVprC8ruaCMuUcLwVvpXMA1EFVUqpo49pcDZSyLuvWtrUQTSklFRQqJ5uWMKiMaRy_QT9PvtOuGaC1OTuaXk_RDyYedDBev9-Mfqu7sNdcspIrng1-nA1i-LuDNOvBJwt9b0YIu6RzZFXleE7zKTmd2hhSiuAuMZToIxWdqehMRWcq-kglS77__95F8IaB_wOsI4zg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1416694431</pqid></control><display><type>article</type><title>Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shen, Yan-Ying ; Lu, Ya-Chao ; Shen, Dan-Ping ; Liu, Yuan-Jie ; Su, Xin-Ying ; Zhu, Guan-Shan ; Yin, Xiao-Lu ; Ni, Xing-Zhi</creator><creatorcontrib>Shen, Yan-Ying ; Lu, Ya-Chao ; Shen, Dan-Ping ; Liu, Yuan-Jie ; Su, Xin-Ying ; Zhu, Guan-Shan ; Yin, Xiao-Lu ; Ni, Xing-Zhi</creatorcontrib><description>To investigate the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and to investigate any associations between this polymorphism and clinicopathological parameters and survival.
Tumors and matched adjacent non-cancer tissues were collected from 304 GC patients, and 5 mL of venous blood was collected from 62 GC patients and 392 age- and sex-matched healthy controls without cancer history from the same ethnic population. DNA was extracted, and direct sequencing analyses were performed to genotype the FGFR4 Gly388Arg polymorphism in all the samples. Differences in the genotype frequencies of the FGFR4 Gly388Arg polymorphism between GC patients and healthy controls were estimated using the χ(2) test. Binary logistic regression was used for all analysis variables to estimate risk as the ORs with 95%CIs. The relationships between the FGFR4 genotype and clinicopathological parameters were tested with the χ(2) test. The Kaplan-Meier product-limit method, the log-rank test, and the Cox regression model were applied to evaluate the effect of the FGFR4 genotype on the overall survival of patients with GC.
In the present GC cohort, 118 patients (38.8%) were homozygous for the Gly388 allele, 124 patients (40.8%) were heterozygous, and 62 patients (20.4%) were homozygous for the Arg388 allele. The frequencies of the Gly/Gly, Gly/Arg, and Arg/Arg genotypes in the healthy controls were 33.6%, 48.0%, and 18.4%, respectively. The distributions of genotypes (χ(2) = 3.589, P = 0.166) and alleles (χ(2) = 0.342, P = 0.559) of the FGFR4 Gly388Arg polymorphism were not different between the GC patients and the healthy controls. Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v19.i28.4568</identifier><identifier>PMID: 23901234</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Co., Limited</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Asian Continental Ancestry Group - genetics ; Brief ; Case-Control Studies ; Cell Differentiation ; Chi-Square Distribution ; China - epidemiology ; Female ; Fibroblast Growth Factor 4 - genetics ; Gene Frequency ; Genetic Predisposition to Disease ; Heterozygote ; Homozygote ; Humans ; Kaplan-Meier Estimate ; Logistic Models ; Male ; Middle Aged ; Neoplasm Staging ; Phenotype ; Polymorphism, Genetic ; Prognosis ; Proportional Hazards Models ; Risk Factors ; Stomach Neoplasms - ethnology ; Stomach Neoplasms - genetics ; Stomach Neoplasms - mortality ; Tumor Burden ; Young Adult</subject><ispartof>World journal of gastroenterology : WJG, 2013-07, Vol.19 (28), p.4568-4575</ispartof><rights>2013 Baishideng Publishing Group Co., Limited. All rights reserved. 2013</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-128ff3543d7ffee1fe651181bfdfdfbe57959dcd944b577141e6f7bd02e6aabf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725383/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725383/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23901234$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Yan-Ying</creatorcontrib><creatorcontrib>Lu, Ya-Chao</creatorcontrib><creatorcontrib>Shen, Dan-Ping</creatorcontrib><creatorcontrib>Liu, Yuan-Jie</creatorcontrib><creatorcontrib>Su, Xin-Ying</creatorcontrib><creatorcontrib>Zhu, Guan-Shan</creatorcontrib><creatorcontrib>Yin, Xiao-Lu</creatorcontrib><creatorcontrib>Ni, Xing-Zhi</creatorcontrib><title>Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients</title><title>World journal of gastroenterology : WJG</title><addtitle>World J Gastroenterol</addtitle><description>To investigate the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and to investigate any associations between this polymorphism and clinicopathological parameters and survival.
Tumors and matched adjacent non-cancer tissues were collected from 304 GC patients, and 5 mL of venous blood was collected from 62 GC patients and 392 age- and sex-matched healthy controls without cancer history from the same ethnic population. DNA was extracted, and direct sequencing analyses were performed to genotype the FGFR4 Gly388Arg polymorphism in all the samples. Differences in the genotype frequencies of the FGFR4 Gly388Arg polymorphism between GC patients and healthy controls were estimated using the χ(2) test. Binary logistic regression was used for all analysis variables to estimate risk as the ORs with 95%CIs. The relationships between the FGFR4 genotype and clinicopathological parameters were tested with the χ(2) test. The Kaplan-Meier product-limit method, the log-rank test, and the Cox regression model were applied to evaluate the effect of the FGFR4 genotype on the overall survival of patients with GC.
In the present GC cohort, 118 patients (38.8%) were homozygous for the Gly388 allele, 124 patients (40.8%) were heterozygous, and 62 patients (20.4%) were homozygous for the Arg388 allele. The frequencies of the Gly/Gly, Gly/Arg, and Arg/Arg genotypes in the healthy controls were 33.6%, 48.0%, and 18.4%, respectively. The distributions of genotypes (χ(2) = 3.589, P = 0.166) and alleles (χ(2) = 0.342, P = 0.559) of the FGFR4 Gly388Arg polymorphism were not different between the GC patients and the healthy controls. Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Brief</subject><subject>Case-Control Studies</subject><subject>Cell Differentiation</subject><subject>Chi-Square Distribution</subject><subject>China - epidemiology</subject><subject>Female</subject><subject>Fibroblast Growth Factor 4 - genetics</subject><subject>Gene Frequency</subject><subject>Genetic Predisposition to Disease</subject><subject>Heterozygote</subject><subject>Homozygote</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Phenotype</subject><subject>Polymorphism, Genetic</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>Stomach Neoplasms - ethnology</subject><subject>Stomach Neoplasms - genetics</subject><subject>Stomach Neoplasms - mortality</subject><subject>Tumor Burden</subject><subject>Young Adult</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc2L2zAQxUVp6Wa3vfdUdOzFWX3Zki-FELofENjL9liELI8cLbblSk6W_PdVSDZ0mcMMzLz3Bn4IfaNkyaVQt68v3XJP66VnainKSn1AC8ZoXTAlyEe0oITIouZMXqHrlF4IYZyX7DO6YrwmlHGxQH_ufBND05s04y6G13mLnbFziDiChek4CHzfH7hSq9jhKfSHIcRp69OA_YjXWz9CAtxlffQWWzNaiHgys4dxTl_QJ2f6BF_P_Qb9vvv1vH4oNk_3j-vVprC8ruaCMuUcLwVvpXMA1EFVUqpo49pcDZSyLuvWtrUQTSklFRQqJ5uWMKiMaRy_QT9PvtOuGaC1OTuaXk_RDyYedDBev9-Mfqu7sNdcspIrng1-nA1i-LuDNOvBJwt9b0YIu6RzZFXleE7zKTmd2hhSiuAuMZToIxWdqehMRWcq-kglS77__95F8IaB_wOsI4zg</recordid><startdate>20130728</startdate><enddate>20130728</enddate><creator>Shen, Yan-Ying</creator><creator>Lu, Ya-Chao</creator><creator>Shen, Dan-Ping</creator><creator>Liu, Yuan-Jie</creator><creator>Su, Xin-Ying</creator><creator>Zhu, Guan-Shan</creator><creator>Yin, Xiao-Lu</creator><creator>Ni, Xing-Zhi</creator><general>Baishideng Publishing Group Co., Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130728</creationdate><title>Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients</title><author>Shen, Yan-Ying ; Lu, Ya-Chao ; Shen, Dan-Ping ; Liu, Yuan-Jie ; Su, Xin-Ying ; Zhu, Guan-Shan ; Yin, Xiao-Lu ; Ni, Xing-Zhi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-128ff3543d7ffee1fe651181bfdfdfbe57959dcd944b577141e6f7bd02e6aabf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Brief</topic><topic>Case-Control Studies</topic><topic>Cell Differentiation</topic><topic>Chi-Square Distribution</topic><topic>China - epidemiology</topic><topic>Female</topic><topic>Fibroblast Growth Factor 4 - genetics</topic><topic>Gene Frequency</topic><topic>Genetic Predisposition to Disease</topic><topic>Heterozygote</topic><topic>Homozygote</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Phenotype</topic><topic>Polymorphism, Genetic</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>Stomach Neoplasms - ethnology</topic><topic>Stomach Neoplasms - genetics</topic><topic>Stomach Neoplasms - mortality</topic><topic>Tumor Burden</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Shen, Yan-Ying</creatorcontrib><creatorcontrib>Lu, Ya-Chao</creatorcontrib><creatorcontrib>Shen, Dan-Ping</creatorcontrib><creatorcontrib>Liu, Yuan-Jie</creatorcontrib><creatorcontrib>Su, Xin-Ying</creatorcontrib><creatorcontrib>Zhu, Guan-Shan</creatorcontrib><creatorcontrib>Yin, Xiao-Lu</creatorcontrib><creatorcontrib>Ni, Xing-Zhi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Yan-Ying</au><au>Lu, Ya-Chao</au><au>Shen, Dan-Ping</au><au>Liu, Yuan-Jie</au><au>Su, Xin-Ying</au><au>Zhu, Guan-Shan</au><au>Yin, Xiao-Lu</au><au>Ni, Xing-Zhi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World J Gastroenterol</addtitle><date>2013-07-28</date><risdate>2013</risdate><volume>19</volume><issue>28</issue><spage>4568</spage><epage>4575</epage><pages>4568-4575</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>To investigate the contribution of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism as a genetic risk factor for gastric cancer (GC) and to investigate any associations between this polymorphism and clinicopathological parameters and survival.
Tumors and matched adjacent non-cancer tissues were collected from 304 GC patients, and 5 mL of venous blood was collected from 62 GC patients and 392 age- and sex-matched healthy controls without cancer history from the same ethnic population. DNA was extracted, and direct sequencing analyses were performed to genotype the FGFR4 Gly388Arg polymorphism in all the samples. Differences in the genotype frequencies of the FGFR4 Gly388Arg polymorphism between GC patients and healthy controls were estimated using the χ(2) test. Binary logistic regression was used for all analysis variables to estimate risk as the ORs with 95%CIs. The relationships between the FGFR4 genotype and clinicopathological parameters were tested with the χ(2) test. The Kaplan-Meier product-limit method, the log-rank test, and the Cox regression model were applied to evaluate the effect of the FGFR4 genotype on the overall survival of patients with GC.
In the present GC cohort, 118 patients (38.8%) were homozygous for the Gly388 allele, 124 patients (40.8%) were heterozygous, and 62 patients (20.4%) were homozygous for the Arg388 allele. The frequencies of the Gly/Gly, Gly/Arg, and Arg/Arg genotypes in the healthy controls were 33.6%, 48.0%, and 18.4%, respectively. The distributions of genotypes (χ(2) = 3.589, P = 0.166) and alleles (χ(2) = 0.342, P = 0.559) of the FGFR4 Gly388Arg polymorphism were not different between the GC patients and the healthy controls. Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
Our results suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for GC cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Co., Limited</pub><pmid>23901234</pmid><doi>10.3748/wjg.v19.i28.4568</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2013-07, Vol.19 (28), p.4568-4575 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3725383 |
| source | MEDLINE; Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Asian Continental Ancestry Group - genetics Brief Case-Control Studies Cell Differentiation Chi-Square Distribution China - epidemiology Female Fibroblast Growth Factor 4 - genetics Gene Frequency Genetic Predisposition to Disease Heterozygote Homozygote Humans Kaplan-Meier Estimate Logistic Models Male Middle Aged Neoplasm Staging Phenotype Polymorphism, Genetic Prognosis Proportional Hazards Models Risk Factors Stomach Neoplasms - ethnology Stomach Neoplasms - genetics Stomach Neoplasms - mortality Tumor Burden Young Adult |
| title | Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A40%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20growth%20factor%20receptor%204%20Gly388Arg%20polymorphism%20in%20Chinese%20gastric%20cancer%20patients&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Shen,%20Yan-Ying&rft.date=2013-07-28&rft.volume=19&rft.issue=28&rft.spage=4568&rft.epage=4575&rft.pages=4568-4575&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v19.i28.4568&rft_dat=%3Cproquest_pubme%3E1416694431%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1416694431&rft_id=info:pmid/23901234&rfr_iscdi=true |